XLRN News and Press, Acceleron Pharma Inc. From 12/03/19

The FDA's Oncologic Drugs Advisory Committee will meet  on Wednesday, December 18, to review and discuss Bristol-Myers Squibb's ( BMY -0.4% ) supplemental marketing application seeking approval to use Reblozyl (luspatercept-aamt) to treat patients myelodysplastic syndromes (MDS), spe...

Bristol-Myers Squibb Company (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review of Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for...

Acceleron ( XLRN ) is about to become a commercial stage biotechnology pharmaceutical company because it will soon begin receiving royalties from sales of its recently-approved lead drug. It serves as an example of the need for patient investing strategies in clinical-stage pharmaceutical co...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Tuesday, December 10, 2019 at 6:00 a.m. EST to review highlights from its presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida, on De...

REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients Approval of REBLOZYL marks the first FDA-approved treatment for anemia in beta thalassemia Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (N...

Acceleron Pharma Inc. (XLRN) Q3 2019 Earnings Conference Call November 6, 2019 10:00 AM ET Company Participants Ed Joyce - Director of Investor Relations Habib Dable - Chief Executive Officer Kevin McLaughlin - Chief Financial Officer Todd James - Vice President, Investor Relat...

Image source: The Motley Fool. Acceleron Pharma Inc   (NASDAQ: XLRN) Q3 2019 Earnings Call Nov 6, 2019 , 10:00 a.m. ET Operator Continue reading

It's been an up-and-down kind of year so far for Acceleron Pharma (NASDAQ: XLRN) . In September, the biotech announced disappointing phase 2 results for ACE-083 in treating facioscapulohumeral muscular dystrophy (FSHD) and scrapped its FSHD program. However, Acceleron's shares have rebounde...

The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2019 Q3 earnings Read more ...

– Updated results from MEDALIST Phase 3 trial show 47.1% of patients with anemia associated with myelodysplastic syndromes treated with luspatercept achieved red blood cell transfusion independence for ≥ 8 weeks and median total duration of clinical benefit was 83.6 weeks fo...